Stifel Nicolaus Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
Recursion Pharmaceuticals Analyst Ratings
Schrodinger Analyst Ratings
Nephron Initiates CareDx at Hold Rating With $15 Price Target
Twist Bioscience Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), HilleVax, Inc (HLVX) and Schrodinger (SDGR)
Jefferies Initiates Recursion Pharmaceuticals at Hold With $8 Price Target
Schrodinger Analyst Ratings
Buy Rating for Arcturus Therapeutics: Advancing Clinical Programs and Strengthening Safety Profile
Piper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Arcturus Therapeutics Analyst Ratings
Buy Rating Affirmed: Promising Developments in Arcturus Therapeutics' MRNA Treatments for Rare Diseases
Twist Bioscience Analyst Ratings
Nurix Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Ionis Pharmaceuticals Analyst Ratings
CRISPR Therapeutics Analyst Ratings
Recursion Pharmaceuticals Analyst Ratings
Intellia Therapeutics Analyst Ratings